Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

EQS-Adhoc: Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer


EQS-Ad-hoc: Evotec SE / Key word(s): Personnel
Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer

23-Apr-2024 / 20:38 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Hamburg, Germany – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces the appointment of Dr Christian Wojczewski as Chief Executive Officer of the Company, effective 01 July 2024. Dr Wojczewski holds a degree in chemistry and has over 20 years of experience in various management positions, most recently as CEO of Mediq and at Linde Healthcare.

Dr Mario Polywka, who has led Evotec as Interim CEO since 03 January 2024, will retire from his position at the end of June and will also not seek re-election for his dormant Supervisory Board mandate, which expires with the 2024 Annual General Meeting.

– End of the ad hoc release –

Contact: Volker Braun, EVP Head of Global Investor Relations ESG, Evotec SE, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany, Phone: +49 (0)40 228 999 338, [email protected]



End of Inside Information

23-Apr-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Evotec SE
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info@evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: MDAX, TecDAX
Listed: Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq
EQS News ID: 1887561

 
End of Announcement EQS News Service

1887561  23-Apr-2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1887561&application_name=news&site_id=sharewise~~~202ee175-2c72-4a50-a0f7-89cd8fcfa533

Evotec SE Stock

€9.79
-1.550%
A loss of -1.550% shows a downward development for Evotec SE.
Our community is currently high on Evotec SE with 4 Buy predictions and 1 Sell predictions.
Based on the current price of 9.79 € the target price of 21 € shows a potential of 114.61% for Evotec SE which would more than double the current price.
Like: 0
Share
EQS Group is a leading international provider of regulatory technology in the fields of corporate compliance and investor relations. In working with EQS Group, thousands of companies worldwide inspire trust by fulfilling complex national and international disclosure obligations, minimizing risks and communicating transparently with stakeholders.




Legal notice

Comments